First and Last Name/s of Presenters

Abby MolloyFollow

Mentor/s

Dr. Deschenes

Participation Type

Poster

Abstract

Cancer vaccines are a new, transcendent form of treatment aimed at achieving remission for metastatic melanoma patients. Recent studies have shown that two main forms of these vaccines have emerged: dendritic cell vaccines and personalized neoantigen vaccines. Neither of these types of cancer vaccines are especially effective for the treatment of metastatic melanoma on their own. However, they become much more efficient when utilized in conjunction other immunotherapeutic methods. Dendritic cell vaccines are most effective when used with either Ipilimumab or Interferon-α treatments. Personalized neoantigen vaccines are most productive when used with an anti-PD1 treatment. Each of these vaccines, when paired with these additional treatments, increase T cell productivity, anti-tumor responses, and an overall immune system attack against the malignant cells. Unfortunately, these vaccines are also accompanied by some challenges, most focused upon the toxicity rates that occur from the supplemental treatments. After considering the results of many clinical trials and reviews regarding cancer vaccines, it can be concluded that dendritic cell and personalized neoantigen vaccines are ineffective on their own. The success of these vaccines exponentially increases when they are coupled with additional forms of immunotherapeutic treatments.

College and Major available

Biology

Location

Digital Commons & West Campus 2nd Floor University Commons

Start Day/Time

4-28-2023 12:00 PM

End Day/Time

4-28-2023 2:00 PM

Students' Information

Abby Molloy, Major: Biology, Minor: Sociology, Honors student, Year of Graduation: 2023

Third Prize Writing Across the Curriculum 2023.

Creative Commons License

Creative Commons Attribution-Noncommercial 4.0 License
This work is licensed under a Creative Commons Attribution-Noncommercial-Share Alike 4.0 License.

Share

COinS
 
Apr 28th, 12:00 PM Apr 28th, 2:00 PM

The Juxtaposition of Various Forms of Cancer Vaccines for Metastatic Melanoma

Digital Commons & West Campus 2nd Floor University Commons

Cancer vaccines are a new, transcendent form of treatment aimed at achieving remission for metastatic melanoma patients. Recent studies have shown that two main forms of these vaccines have emerged: dendritic cell vaccines and personalized neoantigen vaccines. Neither of these types of cancer vaccines are especially effective for the treatment of metastatic melanoma on their own. However, they become much more efficient when utilized in conjunction other immunotherapeutic methods. Dendritic cell vaccines are most effective when used with either Ipilimumab or Interferon-α treatments. Personalized neoantigen vaccines are most productive when used with an anti-PD1 treatment. Each of these vaccines, when paired with these additional treatments, increase T cell productivity, anti-tumor responses, and an overall immune system attack against the malignant cells. Unfortunately, these vaccines are also accompanied by some challenges, most focused upon the toxicity rates that occur from the supplemental treatments. After considering the results of many clinical trials and reviews regarding cancer vaccines, it can be concluded that dendritic cell and personalized neoantigen vaccines are ineffective on their own. The success of these vaccines exponentially increases when they are coupled with additional forms of immunotherapeutic treatments.

 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.